Copyright Reports & Markets. All rights reserved.

Global Liposomal-based Drug Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Liposomal-based Drug by Type
    • 1.3.1 Overview: Global Liposomal-based Drug Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Liposomal-based Drug Consumption Value Market Share by Type in 2025
    • 1.3.3 Liposomes Drugs
    • 1.3.4 Lipid Nanoparticle Drugs
  • 1.4 Global Liposomal-based Drug Market by Application
    • 1.4.1 Overview: Global Liposomal-based Drug Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Other
  • 1.5 Global Liposomal-based Drug Market Size & Forecast
  • 1.6 Global Liposomal-based Drug Market Size and Forecast by Region
    • 1.6.1 Global Liposomal-based Drug Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Liposomal-based Drug Market Size by Region, (2021-2032)
    • 1.6.3 North America Liposomal-based Drug Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Liposomal-based Drug Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Liposomal-based Drug Market Size and Prospect (2021-2032)
    • 1.6.6 South America Liposomal-based Drug Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Liposomal-based Drug Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Johnson & Johnson
    • 2.1.1 Johnson & Johnson Details
    • 2.1.2 Johnson & Johnson Major Business
    • 2.1.3 Johnson & Johnson Liposomal-based Drug Product and Solutions
    • 2.1.4 Johnson & Johnson Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.2 Sun Pharmaceutical
    • 2.2.1 Sun Pharmaceutical Details
    • 2.2.2 Sun Pharmaceutical Major Business
    • 2.2.3 Sun Pharmaceutical Liposomal-based Drug Product and Solutions
    • 2.2.4 Sun Pharmaceutical Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sun Pharmaceutical Recent Developments and Future Plans
  • 2.3 CSPC
    • 2.3.1 CSPC Details
    • 2.3.2 CSPC Major Business
    • 2.3.3 CSPC Liposomal-based Drug Product and Solutions
    • 2.3.4 CSPC Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 CSPC Recent Developments and Future Plans
  • 2.4 Kinyond
    • 2.4.1 Kinyond Details
    • 2.4.2 Kinyond Major Business
    • 2.4.3 Kinyond Liposomal-based Drug Product and Solutions
    • 2.4.4 Kinyond Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Kinyond Recent Developments and Future Plans
  • 2.5 Teva
    • 2.5.1 Teva Details
    • 2.5.2 Teva Major Business
    • 2.5.3 Teva Liposomal-based Drug Product and Solutions
    • 2.5.4 Teva Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Teva Recent Developments and Future Plans
  • 2.6 Fudan-Zhangjiang
    • 2.6.1 Fudan-Zhangjiang Details
    • 2.6.2 Fudan-Zhangjiang Major Business
    • 2.6.3 Fudan-Zhangjiang Liposomal-based Drug Product and Solutions
    • 2.6.4 Fudan-Zhangjiang Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Fudan-Zhangjiang Recent Developments and Future Plans
  • 2.7 Zydus Cadila
    • 2.7.1 Zydus Cadila Details
    • 2.7.2 Zydus Cadila Major Business
    • 2.7.3 Zydus Cadila Liposomal-based Drug Product and Solutions
    • 2.7.4 Zydus Cadila Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Zydus Cadila Recent Developments and Future Plans
  • 2.8 TTY Biopharma
    • 2.8.1 TTY Biopharma Details
    • 2.8.2 TTY Biopharma Major Business
    • 2.8.3 TTY Biopharma Liposomal-based Drug Product and Solutions
    • 2.8.4 TTY Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 TTY Biopharma Recent Developments and Future Plans
  • 2.9 Pacira
    • 2.9.1 Pacira Details
    • 2.9.2 Pacira Major Business
    • 2.9.3 Pacira Liposomal-based Drug Product and Solutions
    • 2.9.4 Pacira Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Pacira Recent Developments and Future Plans
  • 2.10 Luye Pharma
    • 2.10.1 Luye Pharma Details
    • 2.10.2 Luye Pharma Major Business
    • 2.10.3 Luye Pharma Liposomal-based Drug Product and Solutions
    • 2.10.4 Luye Pharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Luye Pharma Recent Developments and Future Plans
  • 2.11 Leadiant Biosciences
    • 2.11.1 Leadiant Biosciences Details
    • 2.11.2 Leadiant Biosciences Major Business
    • 2.11.3 Leadiant Biosciences Liposomal-based Drug Product and Solutions
    • 2.11.4 Leadiant Biosciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Leadiant Biosciences Recent Developments and Future Plans
  • 2.12 Ipsen
    • 2.12.1 Ipsen Details
    • 2.12.2 Ipsen Major Business
    • 2.12.3 Ipsen Liposomal-based Drug Product and Solutions
    • 2.12.4 Ipsen Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Ipsen Recent Developments and Future Plans
  • 2.13 Sayre Therapeutics
    • 2.13.1 Sayre Therapeutics Details
    • 2.13.2 Sayre Therapeutics Major Business
    • 2.13.3 Sayre Therapeutics Liposomal-based Drug Product and Solutions
    • 2.13.4 Sayre Therapeutics Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Sayre Therapeutics Recent Developments and Future Plans
  • 2.14 Jazz
    • 2.14.1 Jazz Details
    • 2.14.2 Jazz Major Business
    • 2.14.3 Jazz Liposomal-based Drug Product and Solutions
    • 2.14.4 Jazz Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Jazz Recent Developments and Future Plans
  • 2.15 Alnylam
    • 2.15.1 Alnylam Details
    • 2.15.2 Alnylam Major Business
    • 2.15.3 Alnylam Liposomal-based Drug Product and Solutions
    • 2.15.4 Alnylam Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Alnylam Recent Developments and Future Plans
  • 2.16 Bausch Health
    • 2.16.1 Bausch Health Details
    • 2.16.2 Bausch Health Major Business
    • 2.16.3 Bausch Health Liposomal-based Drug Product and Solutions
    • 2.16.4 Bausch Health Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.16.5 Bausch Health Recent Developments and Future Plans
  • 2.17 Acrotech Biopharma
    • 2.17.1 Acrotech Biopharma Details
    • 2.17.2 Acrotech Biopharma Major Business
    • 2.17.3 Acrotech Biopharma Liposomal-based Drug Product and Solutions
    • 2.17.4 Acrotech Biopharma Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.17.5 Acrotech Biopharma Recent Developments and Future Plans
  • 2.18 Takeda
    • 2.18.1 Takeda Details
    • 2.18.2 Takeda Major Business
    • 2.18.3 Takeda Liposomal-based Drug Product and Solutions
    • 2.18.4 Takeda Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.18.5 Takeda Recent Developments and Future Plans
  • 2.19 Chiesi Farmaceutici
    • 2.19.1 Chiesi Farmaceutici Details
    • 2.19.2 Chiesi Farmaceutici Major Business
    • 2.19.3 Chiesi Farmaceutici Liposomal-based Drug Product and Solutions
    • 2.19.4 Chiesi Farmaceutici Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.19.5 Chiesi Farmaceutici Recent Developments and Future Plans
  • 2.20 Gilead Sciences
    • 2.20.1 Gilead Sciences Details
    • 2.20.2 Gilead Sciences Major Business
    • 2.20.3 Gilead Sciences Liposomal-based Drug Product and Solutions
    • 2.20.4 Gilead Sciences Liposomal-based Drug Revenue, Gross Margin and Market Share (2021-2026)
    • 2.20.5 Gilead Sciences Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Liposomal-based Drug Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Liposomal-based Drug by Company Revenue
    • 3.2.2 Top 3 Liposomal-based Drug Players Market Share in 2025
    • 3.2.3 Top 6 Liposomal-based Drug Players Market Share in 2025
  • 3.3 Liposomal-based Drug Market: Overall Company Footprint Analysis
    • 3.3.1 Liposomal-based Drug Market: Region Footprint
    • 3.3.2 Liposomal-based Drug Market: Company Product Type Footprint
    • 3.3.3 Liposomal-based Drug Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Liposomal-based Drug Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Liposomal-based Drug Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Liposomal-based Drug Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Liposomal-based Drug Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Liposomal-based Drug Consumption Value by Type (2021-2032)
  • 6.2 North America Liposomal-based Drug Market Size by Application (2021-2032)
  • 6.3 North America Liposomal-based Drug Market Size by Country
    • 6.3.1 North America Liposomal-based Drug Consumption Value by Country (2021-2032)
    • 6.3.2 United States Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Liposomal-based Drug Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Liposomal-based Drug Consumption Value by Type (2021-2032)
  • 7.2 Europe Liposomal-based Drug Consumption Value by Application (2021-2032)
  • 7.3 Europe Liposomal-based Drug Market Size by Country
    • 7.3.1 Europe Liposomal-based Drug Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 7.3.3 France Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Liposomal-based Drug Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Liposomal-based Drug Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Liposomal-based Drug Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Liposomal-based Drug Market Size by Region
    • 8.3.1 Asia-Pacific Liposomal-based Drug Consumption Value by Region (2021-2032)
    • 8.3.2 China Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 8.3.5 India Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Liposomal-based Drug Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Liposomal-based Drug Consumption Value by Type (2021-2032)
  • 9.2 South America Liposomal-based Drug Consumption Value by Application (2021-2032)
  • 9.3 South America Liposomal-based Drug Market Size by Country
    • 9.3.1 South America Liposomal-based Drug Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Liposomal-based Drug Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Liposomal-based Drug Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Liposomal-based Drug Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Liposomal-based Drug Market Size by Country
    • 10.3.1 Middle East & Africa Liposomal-based Drug Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Liposomal-based Drug Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Liposomal-based Drug Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Liposomal-based Drug Market Drivers
  • 11.2 Liposomal-based Drug Market Restraints
  • 11.3 Liposomal-based Drug Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Liposomal-based Drug Industry Chain
  • 12.2 Liposomal-based Drug Upstream Analysis
  • 12.3 Liposomal-based Drug Midstream Analysis
  • 12.4 Liposomal-based Drug Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Liposomal-based Drug market size was valued at US$ 6801 million in 2025 and is forecast to a readjusted size of US$ 12960 million by 2032 with a CAGR of 9.8% during review period.
    Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
    The liposomes nanoparticle drugs market is driven by the increasing demand for targeted drug delivery systems and the potential of liposomes to improve therapeutic efficacy. Liposomes are nanoscale vesicles composed of lipid bilayers that can encapsulate various drugs and deliver them to specific target sites in the body. This targeted drug delivery offers benefits such as reduced side effects, improved drug bioavailability, and enhanced therapeutic outcomes. As the prevalence of chronic diseases rises and the need for personalized medicine grows, liposomes nanoparticle drugs gain popularity in the pharmaceutical industry. Moreover, advancements in nanotechnology and biopharmaceutical research have led to the development of innovative liposomal formulations for a wide range of diseases. However, the market also faces challenges, including the high costs associated with liposomal drug development and production. Additionally, regulatory complexities related to nanomedicines and the need for comprehensive safety evaluations pose obstacles to market growth. To leverage the market"s potential fully, manufacturers need to focus on cost-effectiveness, quality assurance, and robust clinical data to gain regulatory approvals and establish the efficacy and safety of liposomes nanoparticle drugs.
    This report is a detailed and comprehensive analysis for global Liposomal-based Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Liposomal-based Drug market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Liposomal-based Drug market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Liposomal-based Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Liposomal-based Drug market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Liposomal-based Drug
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Liposomal-based Drug market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Liposomal-based Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Liposomes Drugs
    Lipid Nanoparticle Drugs
    Market segment by Application
    Hospital
    Retail Pharmacy
    Other
    Market segment by players, this report covers
    Johnson & Johnson
    Sun Pharmaceutical
    CSPC
    Kinyond
    Teva
    Fudan-Zhangjiang
    Zydus Cadila
    TTY Biopharma
    Pacira
    Luye Pharma
    Leadiant Biosciences
    Ipsen
    Sayre Therapeutics
    Jazz
    Alnylam
    Bausch Health
    Acrotech Biopharma
    Takeda
    Chiesi Farmaceutici
    Gilead Sciences
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Liposomal-based Drug product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Liposomal-based Drug, with revenue, gross margin, and global market share of Liposomal-based Drug from 2021 to 2026.
    Chapter 3, the Liposomal-based Drug competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Liposomal-based Drug market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Liposomal-based Drug.
    Chapter 13, to describe Liposomal-based Drug research findings and conclusion.

    Buy now